Suggested remit - To appraise the clinical and cost effectiveness of cannabidiol within its marketing authorisation for adjuvant treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome.
Status In progress
Process STA 2018
ID number 1211

Provisional Schedule

Expected publication 18 December 2019

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews


Companies sponsors GW Pharma
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Dravet Syndrome UK
  Epilepsy Action
  Epilepsy Society
Professional groups Association of British Neurologists
  Primary Care and Community Neurology Society
  Royal College of Physicians


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (clobazam, topiramate) (not participating)
  Atnahs Pharma UK (clobazam) (not participating)
  Aurobindo Pharma - Milpharm (topiramate) (not participating)
  Biocodex (stiripentol) (not participating)
  Desitin Pharma (sodium valproate) (not participating)
  Janssen (topiramate) (not participating)
  Martindale Pharma (clobazam) (not participating)
  Mylan (topiramate) (not participating)
  Rosemont Pharmaceuticals (clobazam) (not participating)
  Sandoz (topiramate) (not participating)
  Sanofi (clobazam, sodium valproate) (not participating)
  Thame Laboratories (clobazam) (not participating)
  Wockhardt UK (sodium valproate) (not participating)
  Zentiva (sodium valproate) (not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Epilepsy Group


Key events during the development of the guidance:

Date Update
11 November 2019 - 27 November 2019 Final appraisal document
29 October 2019 Committee meeting: 3
26 September 2019 Committee meeting: 2
23 August 2019 - 16 September 2019 Appraisal consultation: 1
30 July 2019 Committee meeting: 1
14 March 2019 The date of the first Committee meeting has been amended to 30 July 2019.
31 October 2018 Invitation to participate
24 April 2018 In progress, referral
16 January 2018 (10:00) Scoping workshop (London)
21 November 2017 - 19 December 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance